Furosemide 40 mg: Clinical Trials

4 trials of Furosemide 40 mg, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 unknown, 1 not yet recruiting, 1 recruiting. 4 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 34Unknown 2, Not yet recruiting 1, Recruiting 1
Phase 21Unknown 1

Follow Furosemide 40 mg: new trials by email Literature Review of Furosemide 40 mg trials Research Report on Furosemide 40 mg

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Improvement of Quality of Life Through Supportive Treatments for Hormone Therapy - Related Symptoms in Patients With Early Breast Cancer
Duloxetine 60 MG, Furosemide 40 mg, Booklet for healthy behaviors - ER+ Breast Cancer, HER2-negative Breast Cancer
Phase 3Not yet recruitingEuropean Organisation for Research and Treatment of Cancer - EORTC3992024-12-012024-11-05
The Impact of Inhaled Furosemide and Perorally Administered Levodropropizine on Dyspnea in Patients With Respiratory Diseases
Furosemide 40 mg, Levodropropizine, Placebo - saline - Dyspnea
Phase 2 / Phase 3UnknownUniversity Hospital Hradec Kralove1022024-02-272024-04-16
Impact of Forced Diuresis on the Residual Fragment Rate After Flexible Ureteroscopy for Destruction of Kidney Stones With Laser
Furosemide 40 mg - Kidney Stone
Phase 3RecruitingUniversity Hospital, Tours3742024-01-042026-11-09
Effect of Furosemide on ESWL Outcomes for Renal and Ureteral Calculi
Furosemide 40 mg, Conventional Treatment - Urolithiasis, Nephrolithiasis
Phase 3UnknownShiraz University of Medical Sciences5002020-07-012022-03-08

Conditions studied

Breast Neoplasms (1)  ·  Drug-Related Side Effects and Adverse Reactions (1)  ·  Dyspnea (1)  ·  Kidney Calculi (1)  ·  Musculoskeletal Pain (1)  ·  Nephrolithiasis (1)  ·  Ureterolithiasis (1)  ·  Urinary Calculi (1)  ·  Urolithiasis (1)

Sponsors

European Organisation for Research and Treatment of Cancer - EORTC (1)  ·  Shiraz University of Medical Sciences (1)  ·  University Hospital Hradec Kralove (1)  ·  University Hospital, Tours (1)

Countries

Czechia (1)  ·  France (1)  ·  Iran (1)

Top investigators

Dariush Irani, MD (1)  ·  Vladimir Koblizek, PhD (1)

Results publications

PMID 38965611

NIH funding

2018 (1)